Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Editas Medicine, Inc. EDIT

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.11
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 3 — — 3 — — 3 1 1 3
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
417.74
Revenue
47.01
Net Income
(73.95)
Free Cash Flow
(120.28)
Net Debt
(211.64)
Current Ratio
3.19
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
6.85
P/B ratio
3.06
Past 5Y EPS Growth
(1.48%)
This Y EPS Growth
56.74%
Next Y EPS Growth
6.81%
Next 5Y EPS Growth
24.69%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 323.11 269.91 146.65 211.65
Receivables 10.19 16.27 15.18 2.73
Inventory — — — —
Other — — — —
340.83 289.32 163.90 218.07
2023 2024 2025 Q'26
Payables 8.27 5.49 2.61 4.74
ST’ Debt — — — —
Other — 5.00 5.00 7.50
63.22 77.23 46.25 68.43
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 2.83 11.89 — —
—
’25 4.66 3.58 7.54 24.74
40.52
’24 1.14 0.51 0.06 30.61
32.31
’23 9.85 2.89 5.34 60.05
78.12
’22 6.77 6.36 0.04 6.54
19.71
’21 6.50 0.38 6.20 12.47
25.54
’20 5.72 10.75 62.84 11.42
90.73
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (23.06) (29.57) — —
—
’25 (47.80) (50.21) (30.84) (36.39)
(165.24)
’24 (49.87) (57.06) (52.59) (50.76)
(210.28)
’23 (35.77) (38.71) (35.46) (22.24)
(132.18)
’22 (49.23) (37.84) (48.00) (42.27)
(177.35)
’21 (49.48) (38.96) (40.78) (34.58)
(163.80)
’20 (54.09) (30.86) (54.80) (40.10)
(179.84)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (23.00) (29.67) — —
—
’25 (47.91) (50.06) (31.28) (36.33)
(165.58)
’24 (51.74) (60.56) (55.51) (51.30)
(219.11)
’23 (37.61) (40.04) (35.70) (23.55)
(136.90)
’22 (51.47) (38.46) (48.62) (42.90)
(181.45)
’21 (49.56) (41.66) (43.13) (37.43)
(171.78)
’20 (56.24) (32.68) (56.59) (41.48)
(186.99)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.26) (0.15) — —
—
’25 (0.92) (0.63) (0.28) (0.06)
(1.80)
’24 (0.76) (0.82) (0.75) (0.55)
(2.88)
’23 (0.71) (0.56) (0.55) (0.23)
(2.02)
’22 (0.74) (0.78) (0.81) (0.88)
(3.21)
’21 (0.86) (0.81) (0.57) (0.61)
(2.85)
’20 (0.69) (0.43) 0.12 (1.00)
(1.98)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.21 6.08 1.16 0.91 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.99 11.93 11.58 4.54 — — —
High Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 226 265 246 87 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.09 0.29 0.13 0.47 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.71 78.12 32.31 40.52 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (220.43) (153.22) (237.09) (160.06) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,118.26%) (196.13%) (733.72%) (395.01%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (220.43) (153.22) (237.09) (160.06) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.61 1.24 0.02 4.38 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.29 1.03 0.39 0.46 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.21) (2.02) (2.88) (1.80) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.58) (1.74) (2.55) (1.86) ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.06) (0.06) (0.11) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.64) (1.80) (2.66) (1.87) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.25 4.60 1.63 0.31 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 68.67 75.97 82.34 88.75 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 29.40 9.70 3.24 4.49 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.61 2.17 0.78 6.67 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.16 6.01 (4.05) 1.73 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.54) (3.43) 0.60 (0.42) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (177.35) (132.18) (210.28) (165.24) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.10) (4.72) (8.83) (0.34) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (181.45) (136.90) (219.11) (165.58) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 296.64 277.61 212.09 117.65 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.95 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (300.33) (323.11) (269.91) (146.64) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 360.68 349.10 134.27 27.29 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (36.99%) (30.24%) (56.40%) (60.61%) ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (233.99%) (406.90%) 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (48.22%) (43.17%) (98.10%) (198.14%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Editas Medicine (EDIT), a CRISPR pioneer targeting genetic diseases, stands at a pivotal crossroads in early 2026, with shares languishing at depressed levels after a brutal post-2021 biotech bust. Once soaring past $99 on milestone payments and hype, the stock has cratered 96% amid clinical disappointments like the RUBY trial flop, evaporating revenues, and patent battles—mirroring sector volatility. Yet, analysts flash bullish signals, with price targets suggesting 161% mean upside (highs at 639%), betting on pipeline catalysts despite forecasts of revenue plunging to $12.7 million by 2027 and relentless cash burn nearing $324 million in FCF losses.

Financials paint a stark picture of dependency on lumpy partnership income: revenues peaked at $90.7 million in 2020 before halving repeatedly, with gross margins holding at 100% but efficiency metrics like revenue per share tanking 75% to 0.13 projected. Losses deepened to -$237 million net income in 2024, ROE at -0.98, and book value per share shriveled 76% to $1.63—yielding dirt-cheap valuations at 0.78x PB and 3.24x PS. Insider selling (no buys) adds caution, but deleveraging and stabilized headcount hint at resilience.

The real intrigue lies in Editas’s CRISPR arsenal—next-gen in vivo editing and sickle cell hopefuls like EDIT-301—poised for Phase 2 wins or deals to reverse the bleed. Trading like a high-stakes turnaround at sub-1x book value, EDIT offers asymmetric upside for patient, risk-tolerant investors in CRISPR’s maturing saga, but demands clinical proof amid dilution risks and competition.

Read full commentary →

Editas Medicine, Inc. (EDIT) Latest News

News by impact score

Fine-tune

11 Sep

4 www.marketbeat.com, 9:01 PM
Editas Medicine targets 2026 patient dosing for LDL gene-editing therapy. 2026 dosing target for LDL gene-editing therapy marks critical pipeline milestone for core gene-editing operations.

9 Sep

4 www.marketbeat.com, 7:02 AM
Editas Medicine advances EDIT-401, its CRISPR therapy targeting cholesterol, toward first human trial. First human trial of EDIT-401 marks major clinical milestone that can drive pipeline value and investor sentiment.

6 Aug

3 , 11:26 AM
Editas Medicine beat Q2 earnings estimates with higher revenues as pipeline developments remain in focus. Earnings beat and revenue growth signal moderate short-term positive effects on performance.

5 Aug

4 , 4:01 PM
Editas Medicine reported second quarter 2026 financial results and business updates. Quarterly results and business updates typically disclose financial metrics and pipeline progress that drive major shifts in valuation and strategy.

26 May

3 GlobeNewswire, 9:05 AM
Editas Medicine priced a public offering of up to $319.4 million. Capital raise affects cash position and share count but represents routine biotech financing without altering core trajectory.

3 GlobeNewswire, 6:15 AM
Editas Medicine, Inc. announced a proposed public offering of its shares to raise capital. Proposed public offering will likely cause share dilution and provide operational funding affecting valuation.

3 GlobeNewswire, 6:01 AM
Editas Medicine presented EDIT-401 preclinical data at the 94th European Atherosclerosis Society Congress demonstrating robust reductions in LDL-C, Lp(a), and ApoB in non-human primates. Positive preclinical results for EDIT-401 may enhance innovation perception but remain early-stage without clinical validation or revenue impact.

6 May

3 Zacks, 11:57 AM
Editas Medicine (EDIT) reported a narrower-than-expected Q1 loss, shifting investor focus to its gene-editing pipeline progress and upcoming milestones. Narrower Q1 loss beat expectations and pipeline highlights offer moderate financial and strategic uplift without transformative changes.

5 May

3 Zacks, 8:25 AM
Editas Medicine (EDIT) reported a Q1 loss and missed revenue estimates. Q1 loss and revenue shortfall highlight financial weakness, likely denting short-term market sentiment and performance.

3 GlobeNewswire, 7:00 AM
Editas Medicine announced first quarter 2026 financial results and provided business updates. Quarterly earnings and business updates moderately influence financial performance and investor sentiment.

27 Mar

4 GlobeNewswire, 7:00 AM
U.S. Patent and Trademark Office reaffirms prior decision favoring Broad Institute in CRISPR/Cas9 patent interference involving Editas Medicine. Reaffirmation strengthens Broad Institute's CRISPR/Cas9 patent dominance, restricting Editas Medicine's IP position and gene editing capabilities.

17 Mar

4 www.fool.com, 5:50 PM
Editas Medicine (EDIT) faces severe risks that could drive its stock price to zero. Existential threat of stock value collapsing to zero poses major risks to future viability and market performance.

15 Mar

4 www.marketbeat.com, 1:37 PM
Editas Medicine outlines in vivo CRISPR editing strategy, targeting first human proof-of-concept data for EDIT-401 by year-end. Targeting year-end human proof-of-concept for in vivo CRISPR therapy EDIT-401 marks a significant pipeline advancement boosting investor sentiment.

10 Mar

3 Zacks, 11:09 AM
Editas Medicine (EDIT) stock rose after reporting a narrower-than-expected Q4 loss and year-over-year revenue increase. Narrower Q4 loss than expected and Y/Y revenue growth signal improved financial performance with moderate positive impact on market sentiment.

9 Mar

3 Zacks, 8:15 AM
Editas Medicine (EDIT) reported a Q4 net loss but exceeded revenue estimates. Q4 loss with revenue beat affects financial performance and short-term market sentiment moderately.

3 Associated Press Finance, 7:11 AM
Editas Medicine (EDIT) released Q4 earnings snapshot detailing financial results. Q4 earnings snapshot provides key financial metrics influencing short-term market sentiment and performance.

3 GlobeNewswire, 7:00 AM
Editas Medicine announced fourth quarter and full year 2025 financial results and business updates. Quarterly earnings and business updates influence financial performance and market sentiment but are routine disclosures.

9 Feb

3 Simply Wall St., 6:03 AM
Editas Medicine, Inc. (NASDAQ:EDIT) faces significant risks as the biotechnology sector is characterized by high volatility and uncertainty. The company is involved in gene editing technologies, which, while promising, come with challenges such as regulatory hurdles, competition, and the need for substantial funding. Investors should be cautious, as the potential for high returns is accompanied by the risk of substantial losses. The biotechnology sector's inherent volatility and regulatory challenges may moderately influence Editas Medicine's financial performance and market positioning.

10 Dec

3 Zacks, 11:30 AM
Editas Medicine, Inc. (EDIT) has seen an 8.3% decline in its stock price since the last earnings report, raising concerns about its ability to rebound. The company is navigating challenges in the competitive landscape of gene editing and biotechnology, which may impact investor sentiment and future performance. Analysts are closely monitoring developments that could influence Editas's trajectory in the coming months. The stock decline reflects moderate concerns about competitive pressures and future performance.

25 Nov

3 Zacks, 10:43 AM
Biogen has entered into a research collaboration with Dayra to enhance its immunology pipeline. This partnership aims to leverage Dayra's innovative technologies to develop new therapies targeting immune-mediated diseases. The collaboration is expected to accelerate Biogen's research efforts and expand its portfolio in the immunology sector, which is a strategic focus for the company. The collaboration may enhance Biogen's product innovation and competitive positioning in immunology, but its direct impact on Editas Medicine's trajectory is limited.

20 Nov

4 ZacksMT NewswiresSimply Wall St.Simply Wall St.MT NewswiresMT Newswires, 11:38 AM
Editas Medicine, Inc. (EDIT) has seen a significant increase in its stock price, soaring 120% over the past month. This surge is attributed to positive developments in the company's gene-editing technology and potential partnerships that could enhance its market position. Investors are optimistic about the future prospects of Editas, particularly in the context of advancements in CRISPR technology and its applications in treating genetic disorders. The substantial stock increase reflects significant investor confidence driven by advancements in gene-editing technology and potential partnerships.

3 Business Wire, 8:00 AM
Cassidy Bio has launched with a mission to create safer and more scalable gene editing therapies. The company aims to address the challenges associated with current gene editing technologies, focusing on improving safety and efficiency in therapeutic applications. This initiative could potentially enhance the landscape of gene editing and provide new solutions for genetic disorders. The launch of Cassidy Bio may influence competitive positioning in the gene editing market, impacting Editas Medicine's operations and market sentiment.

18 Nov

4 Zacks, 8:48 AM
Editas Medicine, Inc. (EDIT) is highlighted as one of the top genomics stocks to consider for investment. The company focuses on gene editing technologies, particularly CRISPR, which have significant potential in treating genetic disorders. With advancements in its pipeline and collaborations with other biotech firms, Editas is positioned to capitalize on the growing demand for innovative genomic therapies. Investors are encouraged to evaluate its performance and market trends as the company continues to develop its product offerings. Significant advancements in gene editing technologies and collaborations could alter Editas's market position and investor sentiment.

13 Nov

4 Simply Wall St., 6:19 AM
Editas Medicine, Inc. reported its latest earnings, leading analysts to revise their estimates upward. The company's performance has prompted a positive shift in market sentiment, reflecting confidence in its future prospects and potential growth in the biotechnology sector. Analysts boosting their estimates indicates significant confidence in Editas Medicine's future performance and market position.

11 Nov

3 ZacksZacksAssociated Press Finance, 10:37 AM
Editas Medicine, Inc. reported a narrower-than-expected loss for Q3, with revenues showing a year-over-year increase. The company's financial performance indicates progress in its operations and potential for future growth. The revenue increase and improved loss position suggest a moderately positive influence on financial performance and market sentiment.

10 Nov

4 GlobeNewswire, 7:00 AM
Editas Medicine, Inc. reported its third quarter 2025 financial results, highlighting advancements in its gene-editing technologies and ongoing clinical trials. The company noted progress in its pipeline, including updates on its lead product candidates and collaborations. Financial metrics showed a year-over-year increase in revenue, driven by partnerships and grants. Editas also provided guidance for the upcoming quarters, emphasizing its commitment to innovation in genetic medicine. Significant advancements in gene-editing technologies and clinical trial progress are likely to impact future performance and investor sentiment.

3 , 8:25 AM
Editas Medicine, Inc. (EDIT) reported a loss for Q3 but exceeded revenue estimates. The company continues to focus on its gene-editing technology and pipeline development, which may influence future performance. Investors are closely monitoring the company's progress and strategic initiatives. The revenue beat indicates potential for improved financial performance, but the loss suggests ongoing challenges.

3 Associated Press Finance, 7:24 AM
Editas Medicine, Inc. reported its Q3 earnings, highlighting key financial metrics and developments in its gene-editing technology. The company continues to advance its pipeline, focusing on innovative treatments for genetic disorders. Despite challenges in the market, Editas remains committed to its strategic goals and aims to enhance shareholder value through ongoing research and development efforts. The earnings report reflects moderate progress in product development and financial performance, which may influence investor sentiment but is balanced by existing market challenges.

3 Nov

3 , 9:00 AM
Editas Medicine, Inc. announced the presentation of a poster on EDIT-401 at the American Heart Association (AHA) Scientific Sessions 2025. This presentation will highlight the latest findings and advancements related to EDIT-401, a potential treatment for certain genetic disorders. The event is expected to attract significant attention from the scientific community and stakeholders in the cardiovascular field. The presentation of EDIT-401 at a prominent scientific conference may enhance visibility and interest in the company's research, potentially influencing its competitive positioning.

9 Oct

4 GlobeNewswireInsider MonkeyMT NewswiresPharmaceutical TechnologyMT NewswiresClinical Trials ArenaInsider MonkeyPharmaceutical Technology, 11:01 AM
Editas Medicine, Inc. presented in vivo proof-of-concept data for its EDIT-401 program at the European Society of Gene and Cell Therapy's 32nd Annual Congress. The data demonstrated the potential of EDIT-401 in treating genetic disorders, highlighting the company's advancements in gene editing technology and its commitment to developing transformative therapies. The presentation of proof-of-concept data for EDIT-401 could significantly impact Editas Medicine's future trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us